Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: A multicentre, randomised, double-blind, placebo-controlled, phase 2b study

Marcelo E. Bigal, David W. Dodick, Alan M. Rapoport, Stephen D. Silberstein, Yuju Ma, Ronghua Yang, Pippa S. Loupe, Rami Burstein, Lawrence C. Newman, Richard B. Lipton

Research output: Contribution to journalArticle

172 Scopus citations

Fingerprint Dive into the research topics of 'Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: A multicentre, randomised, double-blind, placebo-controlled, phase 2b study'. Together they form a unique fingerprint.

Medicine & Life Sciences